Rivastigmine Patch

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Delirium

Conditions

Delirium, Postoperative Cognitive Dysfunction

Trial Timeline

Dec 1, 2008 → Oct 1, 2010

NCT ID

NCT00835159

About Rivastigmine Patch

Rivastigmine Patch is a approved stage product being developed by Novartis for Delirium. The current trial status is completed. This product is registered under clinical trial identifier NCT00835159. Target conditions include Delirium, Postoperative Cognitive Dysfunction.

What happened to similar drugs?

4 of 12 similar drugs in Delirium were approved

Approved (4) Terminated (3) Active (6)

🔄Suvorexant + PlaceboMerckPhase 3

✅Rivastigmine + PlaceboNovartisApproved

🔄Rivastigmine prevention of deliriumNovartisPhase 3

🔄Rivastigmine transdermal patch + placebo patchNovartisPhase 3

❌Dexmedetomidine + PlaceboPfizerPhase 3

✅ParecoxibPfizerApproved

❌Dexmedetomidine + PlaceboPfizerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02703636	Approved	Completed	May 9, 2016	May 7, 2018	Mild to Moderate Alzheimer's Disease
NCT01380288	Pre-clinical	Completed	Jun 1, 2011	Dec 31, 2017	Alzheimer's Disease
NCT00835159	Approved	Completed	Dec 1, 2008	Oct 1, 2010	Delirium

Competing Products

17 competing products in Delirium

See all competitors

Product	Company	Stage	Hype Score
Lemborexant 5 mg + Control (placebo) group	Eisai	Phase 2	42
Suvorexant + Placebo	Merck	Phase 3	40
Suvorexant 20 mg + Placebo	Merck	Phase 2	35
Rivastigmine + Placebo	Novartis	Approved	35
Rivastigmine prevention of delirium	Novartis	Phase 3	40
Rivastigmine transdermal patch + placebo patch	Novartis	Phase 3	40
Dexmedetomidine + Placebo	Pfizer	Phase 3	32
Parecoxib	Pfizer	Approved	39
Dexmedetomidine + Placebo	Pfizer	Phase 3	32
Pregabalin	Pfizer	Phase 3	40
Dexmedetomidine + Midazolam	Pfizer	Phase 3	47
Propofol + Dexmedetomidine	Pfizer	Pre-clinical	26
Dexmedetomidine + Saline placebo	Pfizer	Phase 2/3	38
Cyclopofol + Propofol	Haisco Pharmaceutical Group	Approved	39
Dexmedetomidine + Sodium chloride 0.9%	Baxter	Phase 3	37
Dexmedetomidine Hydrochloride Group	Brain Biotech	Approved	40
Dexmedetomidine sublingual film	BioXcel Therapeutics	Phase 2	17